What were the primary drivers of the revenue decrease in the third quarter of 2023?

The primary driver for the 7% decrease in net sales to $2.59 billion for the third quarter of 2023, compared to the same period in 2022, was a 15% decrease in volume. This was partially offset by a 2% increase in price, a 1% favorable impact from currency, and a 5% favorable portfolio and other impact, including contributions from recent acquisitions.

How did the recent acquisitions of Stoller and Symborg impact the financial results?

The acquisitions of Stoller and Symborg, completed in March 2023 for a combined $1.59 billion, contributed to a favorable portfolio and other impact on net sales. In the Crop Protection segment, these acquisitions added approximately $145 million in net sales for the third quarter and $280 million for the nine-month period, helping to offset declines in other areas.

What is the company's outlook for the full year 2023?

Corteva affirmed its full-year 2023 expectations, forecasting net sales in the range of $17.0 billion to $17.3 billion and Operating EBITDA between $3.25 billion and $3.45 billion. Operating Earnings Per Share is expected to be between $2.50 and $2.70.

What significant litigation or environmental matters are impacting the company?

The company is involved in several significant legal and environmental matters, including FTC investigations regarding competition, lawsuits related to the insecticide Lorsban®, and extensive litigation concerning per- and polyfluoroalkyl substances (PFAS) liabilities stemming from legacy EIDP businesses. A major development is the preliminary approval of a $1.185 billion Nationwide Water District Settlement to resolve drinking water claims related to PFAS.

CTA-PB/CTA-PA 10-Q Quarterly Report Q3 FY2023

Summary

EIDP, Inc. (CTA-PB) reported net sales of $2.59 billion for the third quarter of 2023, a decrease of 7% compared to the same period last year. This decline was primarily attributed to a 15% decrease in volume, though partially offset by favorable price increases and portfolio impacts from recent acquisitions. For the nine months ended September 30, 2023, net sales were $13.52 billion, a slight decrease of 1% year-over-year. The company experienced a significant negative impact from foreign currency fluctuations (-2%) and a volume decrease (-10%), which were partially offset by a strong price increase (9%) and favorable portfolio effects. Despite a decrease in net sales for the quarter, the company's Operating EBITDA saw an improvement for the nine-month period compared to the previous year, driven by price execution and cost management. The company also recently completed significant acquisitions, further integrating biological tools into its Crop Protection segment.

Key Highlights

1Net sales for Q3 2023 were $2.59 billion, down 7% year-over-year, driven by a 15% volume decrease.
2Nine-month net sales were $13.52 billion, down 1% year-over-year, with volume declines partially offset by strong price increases.
3The company completed the acquisitions of Stoller Group Inc. and Quorum Vital Investment, S.L. (Symborg) for a combined $1.59 billion, enhancing its biologicals and microbiological technologies offerings.
4Restructuring and asset-related charges decreased significantly to $2 million in Q3 2023 from $152 million in Q3 2022.
5Operating EBITDA for the nine-month period improved to $3.00 billion from $2.94 billion in the prior year, driven by price execution and cost savings.
6The company declared common stock dividends totaling $0.46 per share for the first nine months of 2023, indicating a commitment to returning value to shareholders.
7Corteva affirmed its full-year 2023 outlook, expecting net sales between $17.0 billion and $17.3 billion and Operating EBITDA between $3.25 billion and $3.45 billion.

EIDP, Inc. Quarterly Report for Q3 Ended Sep 30, 2023

Summary

Key Highlights

Frequently Asked Questions